Nature Communications (Nov 2022)

Antigenic sin of wild-type SARS-CoV-2 vaccine shapes poor cross-neutralization of BA.4/5/2.75 subvariants in BA.2 breakthrough infections

  • Bin Ju,
  • Qing Fan,
  • Miao Wang,
  • Xuejiao Liao,
  • Huimin Guo,
  • Haiyan Wang,
  • Xiangyang Ge,
  • Lei Liu,
  • Zheng Zhang

DOI
https://doi.org/10.1038/s41467-022-34400-8
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 6

Abstract

Read online

Updated vaccines based on Omicron subvariants have started to being rolled out. Analysis of antibody response in individuals with two or three vaccine doses suggests that BA.2 breakthrough infection barely increases cross-neutralization capacity against BA.4/5 or BA.2.75.